US EditionPublished • loading... • Updated
Evinacumab-dgnb Approved For Children Aged 1-5 With Rare Form of High Cholesterol | Pharmacy Times - Pharmacy Practice News and Expert Insights
Summary by Pharmacy Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Evinacumab-dgnb Approved For Children Aged 1-5 With Rare Form of High Cholesterol | Pharmacy Times - Pharmacy Practice News and Expert Insights
The angiopoietin-like-3-targeting treatment received an expanded indication for individuals aged 1 through 5 years, building on earlier approvals in older populations.
FDA Approves Evinacumab-Dgnb for Children Aged 1-5 with Rare High Cholesterol Disorder
The U.S. Food and Drug Administration has expanded the […] The post FDA Approves Evinacumab-Dgnb for Children Aged 1-5 with Rare High Cholesterol Disorder first appeared on GeneOnline News. The post FDA Approves Evinacumab-Dgnb for Children Aged 1-5 with Rare High Cholesterol Disorder appeared first on GeneOnline News.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
